Breast Cancer
Pfizer Sutent (6488)
A Phase II Study Evaluating the Safety and Efficacy of Sunitinib Maleate (Sutent) in Combination With Weekly Paclitaxel (Taxol) Followed by Doxorubicin (Adriamycin) and Daily Oral Cyclophosphamide (Cytoxan) Plus G-CSF as Neoadjuvant Chemotherapy for Locally Advanced or Inflammatory Breast Cancer
Investigator: Jennifer Specht, MD; Conditions: Breast Cancer; Status: Recruiting; Study ID: NCT00513695
A Phase III Randomized, Multicenter, Two-Arm, Open-Label Trial to Evaluate the Efficacy of Trastuzumab Emtansine Compared With Treatment of Physician's Choice in Patients With HER2 Positive Metastatic Breast Cancer Who Have Received at Least Two Prior Regimens of HER2 Directed Therapy
Investigator: V.K. Gadi, MD, PhD; Conditions: Breast Cancer; Status: Recruiting; Study ID: NCT01419197
A Study of Trastuzumab-DM1 Plus Pertuzumab Versus Trastuzumab [Herceptin] Plus a Taxane in Patients With Metastatic Breast Cancer (UW10020)
Investigator: Julie R. Gralow, MD; Conditions: Breast Cancer; Status: Recruiting; Study ID: NCT01120184
Phase I/II Study of Adoptive T Cell Therapy Following In Vivo Priming With a HER-2/Neu (HER2) Intracellular Domain (ICD) Peptide-Based Vaccine in Patients With Advanced Stage HER2 Overexpressing Breast Cancer
Investigator: Lupe Salazar, MD; Conditions: Breast Cancer; Status: Recruiting; Study ID: NCT00791037
An Open-Label, Multicenter Extension Study of Trastuzumab-MCC-DM1 (T-DM1) Administered as a Single Agent or in Combination With Other Anti-Cancer Therapies in Patients Previously Treated With the Equivalent T-DM1 Regimen in a Genentech and/or F. Hoffmann-La Roche Ltd.-Sponsored T-DM1 Study (UW10039)
Investigator: Julie R. Gralow, MD; Conditions: Metastatic Breast Cancer; Status: Recruiting; Study ID: NCT00781612
Phase III Randomized Trial of the Effect of Metformin versus Placebo on Recurrence and Survival in Early Stage Breast Cancer
Investigator: Fred Appelbaum, MD; Conditions: Breast Cancer; Status: Recruiting; Study ID: NCT01101438
Combined Targeted Therapies for Triple Negative Advanced Breast Cancer - A Phase II Trial of Weekly Nab-Paclitaxel (Abraxane) and Bevacizumab (Avastin) Followed by Maintenance Targeted Therapy With Bevacizumab (Avastin) and Erlotinib (Tarceva)
Investigator: Jennifer Specht, MD; Conditions: Breast Cancer; Status: Recruiting; Study ID: NCT00733408
A Phase 1 Study of ABT-888 (Veliparib) in Combination With Carboplatin (Paraplatin) and Gemcitabline (Gemzar) in Subjects With Advanced Solid Tumors
Investigator: Heidi J. Gray, MD; Conditions: Advanced Solid Tumors; Status: Not Recruiting; Study ID: NCT01063816
Phase I Study of ABT-888 (Veliparib) in Combination With Cisplatin and Vinorelbine (Navelbine) for Patients With Advanced Triple Negative Breast Cancer and/or BRCA-Mutation Associated Breast Cancer
Investigator: Eve Rodler, MD; Conditions: Advanced Breast Cancer; Status: Recruiting; Study ID: NCT01104259
A Phase I Open-Label, Dose-Escalation Study of the Phosphoinositide 3-Kinase Inhibitor GSK2126458 in Subjects With Solid Tumors or Lymphoma
Investigator: Jennifer Specht, MD; Conditions: Advanced Solid Tumor or Lymphoma; Status: Closed; Study ID: NCT00972686
Randomized Phase 2 Study of MLN8237, an Aurora A Kinase Inhibitor, Plus Weekly Paclitaxel or Weekly Paclitaxel Alone in Patients With Recurrent Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer, Preceded by a Phase 1 Portion in Patients With Ovarian or Breast Cancer
Investigator: Barbara A. Goff, MD; Conditions: Ovarian Carcinoma, Fallopian Tube Cancer, Peritoneal Cancer, Breast Carcinoma; Status: Recruiting; Study ID: NCT01091428
Phase II Study of Topical Imiquimod (Aldara) and Weekly Abraxane for the Treatment of Breast Cancer Cutaneous Metastases
Investigator: Lupe Salazar, MD; Conditions: Breast Cancer, Metastatic Cancer; Status: Recruiting; Study ID: NCT00821964
A Phase 2 Study of [18F]Fluoroestradiol (FES) as a Marker of Hormone Sensitivity of Metastatic Breast Cancer
Investigator: David Mankoff, MD, PhD; Conditions: Breast Cancer; Status: Recruiting; Study ID: NCT00602043
A Phase II Study of the Combination of High-dose Methotrexate and Intrathecal Liposomal Cytarabine in Patients with Parenchymal and Leptomeningeal Metastases from Breast Cancer
Investigator: Maciej Mrugala, MD, PhD; Conditions: Stage IV Breast Cancer, Central Nervous System Involvement/Metastases, Leptomeningeal Metastases, Recurrent Breast Cancer, Tumors Metastatic to Brain; Status: Open; Study ID: NCT00992602
A Phase I Study Evaluating a Second Generation Antisense Oligonucleotide (OGX-427) that Inhibits Heat Shock Protein 27 (Hsp 27)
Investigator: Evan Yu, MD; Conditions: Bladder Cancer; Breast Cancer; Genitourinary Cancer; Gynecological Cancer; Lung Cancer; Ovarian Cancer; Prostate Cancer; Solid Tumors; Status: Recruiting; Study ID: NCT00487786
A Randomized Phase III Trial of Adjuvant Therapy Comparing Chemotherapy Alone (Six Cycles of Docetaxel Plus Cyclophosphamide or Four Cycles of Doxorubicin Plus Cyclophosphamide Followed by Weekly Paclitaxel) to Chemotherapy Plus Trastuzumab (Herceptin) in Women with Node-Positive or High-Risk Node-Negative HER2-Low Invasive Breast Cancer
Investigator: Tanya Wahl, MD; Conditions: Breast Cancer; Status: Recruiting; Study ID: NCT01275677
A Randomized Phase II Trial of Weekly Nanoparticle Albumin Bound Paclitaxel (Nab-Paclitaxel) (NSC-736631) With or Without Bevacizumab, Either Preceded by or Followed By Q 2 Week Doxorubicin (A) and Cyclophosphamide (C) Plus Pegfilgrastim (PEG-G) As Neoadjuvant Therapy for Inflammatory and Locally Advanced Her-2/Neu Negative Breast Cancer
Investigator: Fred Appelbaum, MD; Conditions: Breast Cancer; Status: Recruiting; Study ID: NCT00856492
Phase I-II Study of HER2 Vaccination with poly(I) Poly(C12U) (Ampligen®) as an Adjuvant in Optimally Treated Breast Cancer Patients
Investigator: Lupe Salazar, MD; Conditions: Breast Cancer; Status: Recruiting; Study ID: NCT01355393
Randomized Phase II Trial of Capecitabine and Lapatinib With or Without IMC-A12 in Patients With HER2 Positive Breast Cancer Previously Treated With Trastuzumab and an Anthracycline and/or a Taxane
Investigator: Hannah M. Linden, MD; Conditions: Breast Cancer; Status: Recruiting; Study ID: NCT00684983
A Prospective, Randomized, Double-blind, Stratified, Multi-center, 2-arm Trial of the Continued Efficacy and Safety of Zoledronic Acid (Zometa® ) (Every 4 Weeks vs. Every 12 Weeks) in Patients With Documented Bone Metastases From Breast Cancer
Investigator: Georgiana Ellis, MD; Conditions: Breast Cancer; Status: Recruiting; Study ID: NCT00320710
A Randomized Phase III Trial to Test the Strategy of Changing Therapy Versus Maintaining Therapy for Metastatic Breast Cancer Patients Who Have Elevated Circulating Tumor Cell Levels at First Follow-Up Assessment
Investigator: Frederick Appelbaum, MD; Conditions: Breast Cancer; Status: Recruiting; Study ID: NCT00382018
Randomized Phase III Trial of Paclitaxel Combined With Trastuzumab (Herceptin), Lapatinib (Tykerb), or Both as Neoadjuvant Treatment of Her2-Positive Primary Breast Cancer
Investigator: ; Conditions: Breast Cancer; Status: Recruiting; Study ID: NCT00770809
A Phase 2 Study of [18F]fluoroestradiol (FES) Imaging and Response to Hormonal Therapy
Investigator: David Mankoff, M.D., PhD ; Conditions: Breast Cancer; Status: Recruiting
Positron Emission Tomography (PET) for Evaluation of Breast Cancer Metastases to Bone with [F-18] Fluoride
Investigator: David Mankoff, M.D., PhD; Conditions: Breast Cancer; Status: Recruiting
Imaging Early Response of ER+, HER2- Breast Cancer To Aromatase Inhibitor (AI) Therapy
Investigator: David Mankoff, M.D., PhD ; Conditions: Breast Cancer; Status: Recruiting
A Prospective Observational Multicenter Cohort Study to Assess the Incidence of Osteonecrosis of the Jaw (ONJ) in Cancer Patients with Bone Metastases Starting Zoledronic Acid Treatment
Investigator: Fred Appelbaum, MD; Conditions: Breast Cancer, Lung Cancer, Neoplasm Metastasis, Multiple Myeloma and Plasma Cell Neoplasm, Prostate Cancer, Unspecified Adult Solid Tumor; Status: Recruiting; Study ID: NCT00874211
A Phase III clinical trial of Accelerated Whole Breast Irradiation with Hypofractionation plus concurrent boost versus standard Whole Breast Irradiation plus sequential boost for early-stage breast cancer.
Investigator: George Laramore, MD; Conditions: Breast cancer; Status: Recruiting; Study ID: NCT01349322
Clinical and Biological Characterization of Male Breast Cancer: An International Retrospective EORTC, BIG and NABCG Intergroup Study
Investigator: Larissa Korde, MD; Conditions: Male Breast Cancer; Status: Recruiting; Study ID: NCT01101425
Join Us On